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Abstract
Background: After surgical resection of pancreatic adenocarcinoma, most patients will develop recur-
rence within 2 years. Intense follow-up is often recommended; however, its impact on survival is
unknown. Patient and clinician attitudes towards follow-up were qualitatively assessed along with the
perceived benefits and challenges.
Methods: A semi-structured interview guide was developed. Purposive sampling identified patients who
were in active surveillance or had developed recurrence. Clinicians involved in patient care were also
interviewed. Interviews were conducted until saturation was reached and themes were derived using
standard qualitative methods.
Results: A total of 15 patients and seven clinicians were interviewed. Patient themes included a limited
understanding of disease prognosis, a desire for reassurance, a desire to know if and when recurrence
occurred and minimal difficulties with follow-up. Clinician themes included expectation that patients are
aware of the recurrence risk, a desire to provide reassurance, support for intense follow-up and perceived
patient challenges in follow-up. Overall, the dominant theme was one of disconnect between patients and
clinicians in the understanding of the disease and its prognosis.
Discussion: Patients have an intense need for reassurance and obtain this through follow-up appoint-
ments with their oncologists. Consequently, they express few difficulties with the process. Clinicians
recognize this desire for reassurance. Patients' understanding and expectations contrast starkly with
clinicians' perspectives regarding prognosis.
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Introduction
Pancreatic ductal adenocarcinoma is the 12th most common cancer
in Canada and the United States; however, it is the 4th leading cause
of cancer death.1,2 While surgery remains the only potentially
curative treatment, after resection the 5-year survival rates remain
low at 5–27%.3–6 Unfortunately 80% of patients with pancreatic
cancer will develop a recurrence within the first 2 years after a
resection, for which there are no curative treatment options.7–9
Palliative chemotherapy improves survival in those with a good
performance status; however, the median survival after recurrence
only ranges from 6 to 12 months.10 Clinical trials are therefore
strongly recommended and best supportive care remains a valid
option10 for those who are not fit for chemotherapy. There is no
compelling evidence to suggest that early detection of recurrence or
early initiation of treatment impacts survival.
Some clinicians advocate for intensive surveillance after a resec-
tion of pancreatic cancer owing to the high risk of recurrence.10–12
*Co-first authors.
Portions of this work were presented at the American Society of Clinical
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The National Comprehensive Cancer Network (NCCN) recom-
mends a history and physical examination, laboratory investiga-
tions (including Ca19-9) and computed tomography (CT) every 3
to 6 months for the first 2 years and then annually.10 No
randomized controlled trials have evaluated the benefit of inten-
sive follow-up and data from observational studies have been
conflicting.11,13 A recent analysis suggests that a less intensive
protocol with no routine imaging is the most cost-effective sur-
veillance protocol.14 It should be noted that none of these studies
evaluated the benefit of follow-up in the setting of clinical trials,
where there may be other potential benefits to an intensive
follow-up plan. However, given the lack of strong supporting evi-
dence towards a follow-up protocol, current guidelines are poorly
followed.15
Intensive surveillance carries the potential for harm. Patients
undergoing follow-up testing exhibit significant anxiety and fear of
cancer recurrence, with a substantial impact on quality of life.16–18
False-positive test results followed by additional invasive testing
may perpetuate harm to the patients undergoing intensive surveil-
lance.19 Beyond individual patient harm, there are resource conse-
quences to intensive follow-up and surveillance.19–22
In spite of the high risk of recurrence, the intense follow-up
strategies, and the potential consequences of such regimens, no
qualitative study has previously investigated patient understand-
ing and the impact of surveillance on patients with pancreatic
cancer. This study sought to assess patient and clinician experi-
ences, expectations and attitudes towards surveillance after resec-
tion of pancreatic and peri-ampullary cancer.
Patients and methods
Participants
Patients were recruited from a specialized Hepato-pancreatico-
biliary clinic at the Odette Cancer Centre (OCC), a tertiary cancer
centre at Sunnybrook Health Sciences Centre (SHSC), from
November 2012 to March 2013. Consecutive eligible patients who
had undergone surgical resection of pancreatic or peri-ampullary
adenocarcinoma with curative intent and were undergoing surveil-
lance or had developed recurrence were identified for inclusion in
the study. No patient was enrolled into a clinical trial as none was
being conducted during the study period. No standardized patient
education material, support group or follow-up protocol was avail-
able during this period. In keeping with the qualitative research
design, the sample size was expanded as necessary until redun-
dancy on core issues, known as saturation, was observed.23–26
Informed consent was obtained from each participant prior to the
interview. No additional educational materials were given to
patients beyond that required to obtain informed consent. This
study was approved by the SHSC Research Ethics Board.
Data collection
Each patient completed a questionnaire to supply demographic
and general follow-up information. Pathological information was
obtained through retrospective chart review.
Qualitative methodology and Content Analysis (CA) directed
the generation of the interview guide, data collection and data
analysis. Data collection was accomplished through private semi-
structured interviews to encourage honest opinions and allow for
discussion of sensitive issues.23 Patients were encouraged to bring
a support person, such as a family member; however, the family
member was not interviewed. A single trained researcher (E.C.),
who was not involved in the clinical care of these patients, con-
ducted all the interviews using a semi-structured interview guide.
The interview guide was piloted during the first three inter-
views.23 The interview guide was adjusted to ensure all areas
of interest were addressed. Interviews were conducted once per
participant.
All clinicians in radiation oncology, medical oncology and sur-
gical oncology involved in treating pancreatic adenocarcinoma,
except for those directly involved in this study, were invited to
participate. Semi-structured interviews were conducted with the
clinicians by a single interviewer (E.C.) using a different interview
guide.
The interviewer made notes concerning important interac-
tions, mood or tone of responses, and any other non-verbal
behaviour for both sets of interviews.23
Statistical analysis
Interviews were transcribed verbatim and CA was used to analyse
the data. This is an iterative approach which involves multiple
readings of the transcripts; simultaneous data collection and
analysis generates a coding schema reflecting unique ideas.25–28
Constant comparative analysis of the schema allowed similar
concepts to be grouped together into larger themes driving
the research towards an overarching theory or theme
construction.24–28 Interviews were coded independently by three
investigators (E.C., R.D. and F.C.W.), findings were discussed with
the entire research team and consensus of interpretation was
achieved. One dominant theme or overarching theory was iden-
tified. Descriptive statistical analysis of participant demographics
and clinical characteristics was performed.
Results
Patient characteristics
Seventeen patients were invited to participate in the study;
however, one patient was excluded after the interview owing to a
different histological presentation (intraductal papillary
mucinous neoplasm) and one patient declined to participate as a
result of physical discomfort. Fifteen patients were included in the
analysis. The median time from pancreatic cancer resection to the
interview was 247 days (range 41 to 1140). Patient demographic
and follow-up data are included in Table 1. Three patients had
been diagnosed with recurrence whereas the remaining 12 had no
evidence of disease. Patient pathology and treatment data are
included in Table 2.
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Patient themes (Table 3)
Median interview times for patients were 28 min (range 14 min to
47 min). A family member was present for ten interviews. Satura-
tion was reached after twelve interviews.
Subtheme 1: limited understanding of disease prognosis
Most patients had a vague understanding of the disease and its
prognosis. Some patients understood that it was an ‘aggressive’
cancer. Patients viewed themselves as being cancer free after resec-
tion and most patients with advanced disease did not recognize
their poor prognosis. ‘Hopefully the chemo and radiation will
look after that [positive margin and lymph nodes] and get healthy
for another 30 years’. The effectiveness of treatments was also
Table 1 Patient data
Patients
N = 15
(n)
Age [median (range)]
64 (43–84)
Gender
M 8
F 7
Ethnicity
Caucasian 13
Korean 1
West Indian 1
Partner status
Married 11
Separated 1
Widowed 2
Never married 1
Occupation
Retired 13
Working 2
Highest educational level
High School 7
Undergraduate/College 6
Graduate 2
Distance travelled to cancer centre (km)
<25 8
26–100 5
>100 + 2
Accompaniment to appointments
Yes (family or friend) 13
No 2
Frequency of seeing oncologist(s)
Every month 7
Every 3 months 6
Every 6 months 2
CT scan frequency
Every month 3
Every 3 months 5
Every 6 months 4
Annually 3
CT, computed tomography.
Table 2 Patient pathological and treatment data
Patients
N = 15
(n)
Site of primary
Pancreatic ductal 10
Peri-ampullary 5
TNM stage
T1 N0 1
T2 N1 2
T3 N0 2
T3 N1 9
T4 N1 1
Recurrence
Yes 3
No 12
Chemotherapy received
Yes 14
No 1
Radiation received
Yes 10
No 5
Table 3 Patient themes and quotes
Theme Quote
1 Limited understanding of
prognosis
‘They want to make sure there is no
recurrence and that everything is
working the way it should be [. . .]
and making sure I'm around for
another ten, twenty years!’ (15)
‘Hopefully the chemo and radiation
will look after that [positive margin &
lymph nodes] and get healthy for
another 30 years.’ (11)
2 Reassurance through
follow-up
‘It's that comfortable level of just
seeing them all and having each
one in their own way tell me that
everything's fine’ (6)
3 Desire to know if or when
recurrence occurred
‘We're very educated individuals to be
able to understand the data so it's
better to know than not to know. So
any information that may be
available should be available to us.’
(6)
4 Minimal difficulties with
follow-up protocol
‘Because it was like a walk in the park
like, okay, I come in and
everything's fine and I get to go
away for three months.’ (14)
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overestimated. ‘I would have to do chemo because they see lesions
on my liver and they want to get rid of them before they become
tumors’. Patients with recurrence in particular lacked understand-
ing, often expecting to survive 10 or more years without symp-
toms. ‘I did go to the hospice and I will end up there some year,
maybe ten years’.
Subtheme 2: reassurance through follow-up
Patients experienced reassurance through attending follow-up
appointments and hearing from their oncologists that they did
not have recurrence, including the only two patients who
acknowledged that follow-up was stressful. Many patients
expressed the importance of timely access to clinicians or nurses at
the cancer centre in order to have questions or concerns addressed
between follow-up appointments. Patients did not convey any-
thing specific that was reassuring, but generally conveyed ‘that
comfortable level of just seeing them’ was what was desired. When
‘he says in three months time, I’m going to see you again . . . it’s
giving you hope that everything is going to be okay’.
Subtheme 3: desire to know if or when
recurrence occurred
Patients stated that they would want to know if or when recur-
rence occurred. Some patients felt that early detection of recur-
rence through follow-up would allow for earlier treatment, which
they felt would improve their survival. ‘If something’s going to
show up, get it detected earlier, get it treated’. Others still wished to
know if a recurrence developed in spite of not wanting to receive
further treatment. Despite this desire, few patients reported
knowing or having discussed with their oncologists what the
treatment options would be if a recurrence were detected.
Subtheme 4: minimal difficulties with follow-up protocol
The majority of patients had a positive follow-up experience. This
was expressed through comments such as: ‘It’s been great’, ‘It’s nice
to see them’ and ‘extremely positive’. ‘It’s the people, honest! . . .
Going there is healing’. The frequency of follow-up and travel were
not major challenges for most patients as most were retired or
could easily take time off work. Minor challenges identified
included wait times at the clinic and parking costs. Anxiety as a
result of the overall follow-up process was not a major difficulty
reported by patients. However, patients did not note experiencing
anxiety with CT scans, a few patients identified that CT scans were
the most difficult part of the follow-up process. In some cases this
was clearly because of physical discomfort, not anxiety, for
example, ‘I really hate them [CT scan] and it’s because I have great
difficulty drinking’. Only one patient questioned the utility of a CT
scan detecting a recurrence if she was asymptomatic.
Clinician themes (Table 4)
Seven of the nine eligible clinicians were interviewed including
three medical oncologists, two surgical oncologists and two radia-
tion oncologists. The median interview times for clinicians
were 19 min (range 11–32). Saturation was reached with seven
interviews.
Subtheme 1: think patients are aware of recurrence risk
All the clinicians interviewed stated that they discuss the risk of
recurrence with patients before or after resection so that patients
can understand their treatment options and prognosis. ‘We know
that almost all of them will recur . . . It’d be wrong to have patients
going on thinking “I’m cured. There’s never going to be a problem
again” ’. Some clinicians felt that patients implicitly knew that they
were looking for recurrence with the follow-up protocol, and
consequently did not re-discuss the risk of recurrence at follow-up
visits. ‘They are well aware of their recurrence risk . . . most of
them are already very aware that it’s pretty grave disease’.
Discussion of possible treatment options for recurrent disease
happens rarely during the follow-up period prior to the detection
of recurrence.
Table 4 Clinician themes and quotes
Theme Quote
1 Think patients are aware
of recurrence risk
‘Patients are very intelligent . . . they
know. They will say, “Doctor, you
know, I want you to make sure that I
don't get it again. And if I get it, I
want you to do something and so
forth.” So they are very much
aware.’ (S2)
2 Intense follow-up despite
lack of supporting
evidence
‘Usually after chemo, we initially plan
to scan them once every 6 months
and after 1–2 years, we usually scan
them once a year, even if there's no
evidence supporting that.’ (M2)
3 Desire to provide
reassurance to patients
‘They love to come back . . . unless
unfortunately . . . in pancreatic
cancer, there's a high, high rate of
recurrence, and when that happens,
it's a sad visit. But other than that,
however many times they come
back, and you give them good news
that there's no recurrence, they're
quite happy.’ (S2)
4 Secondary goals for
surveillance
‘I'd rather them know and know at a
time where they're functional rather
than symptomatic so that while
they're functional, they have a better
opportunity to see who they need to
see, close their affairs, get things in
order, or go on that cruise that they
needed to do.’ (S1)
5 Challenges in follow-up ‘There's a huge anxiety that many
patients tell me that they don't sleep
for a week or two before a test [. . .]
so then they have the test and [. . .]
it's a great relief after that, but
they've built up all this anxiety
around the test and at the end of
the day, the test doesn't really
change the day that they're going to
die.’ (M1)
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Subtheme 2: intense follow-up in spite of lack of
supporting evidence
Almost all of the clinicians conducted intense follow-up including
clinical appointments every 3 to 6 months and CT scans and
blood tests every 6 months for the first 2 years. ‘Usually after
chemo, we initially plan to scan them once every 6 months and
after 1–2 years, we usually scan them once a year, even if there’s no
evidence supporting that’. Most acknowledged the lack of evi-
dence to support this approach with statements like ‘we don’t
know if surveillance makes a difference’. In spite of this, many
clinicians believe there are benefits with early palliative therapy
before functional decline when a patient would not be able to
receive treatment. Others described their follow-up protocol as a
routine, ‘it’s just what I’ve been doing in practice’ or ‘It’s what we
do. I’m not sure how else I would do it [follow-up] otherwise’.
Only one clinician reported following patients clinically and tried
to ‘avoid doing blood work or scans unless clinically necessary’.
Subtheme 3: desire to provide reassurance to patients
Most clinicians felt that patients want to have follow-up for
reassurance. One described it as ‘that constant reassurance that
somebody’s with them and somebody’s making a plan for them’.
The clinicians recognized that follow-up could bring ‘peace of
mind’ and provide psychosocial benefits. Some clinicians expected
that patients would be resistant to the proposal of decreased
follow-up.
Subtheme 4: secondary goals for surveillance
Clinicians believe that follow-up can provide additional benefits
for patients beyond early detection and treatment of recurrence.
Post-treatment symptoms can be identified and managed. For
patients who develop recurrence, it provides an opportunity for
end-of-life planning prior to functional decline. It can ‘allow the
patient to know as early as possible what their fate will be’. Other
clinicians desire to maintain the ‘doctor–patient relationship’
through the follow-up process.
Subtheme 5: challenges in follow-up
All clinicians noted significant challenges for patients caused by
the follow-up process. The majority of clinicians identified that
their patients get anxious surrounding follow-up, especially with
CT scans. ‘There’s a lot of anxiety surrounding the whole issue of
follow-up and waiting’. ‘Many patients tell me that they don’t sleep
for a week or two before a test’. Some clinicians also identified the
potential harms of CT scans. Others noted logistical problems for
patients due to travel and time away from work as well as system
challenges due to resource allocation. ‘If you do a lot of follow-up
scans, maybe the next patient who was jaundice . . . you can’t get
time on the CT scan’.
Dominant theme or overarching theory: ‘disconnect
between patients and clinicians in the understanding of
the disease and its prognosis’
The dominant theme identified in this study is disconnect
between patients and clinicians in their understanding of the
disease, its prognosis and the patient’s experience with follow-up.
Clinicians feel patients understand their risk of recurrence and
prognosis, while patients demonstrate unrealistic expectations of
therapy and survival in spite of poor pathological staging or even
recurrence of disease. Patients have an intense desire for reassur-
ance. In response, clinicians offer intensive surveillance in spite of
limited evidence for its benefit and the acknowledgement that
follow-up is anxiety inducing and difficult for patients. Despite
these concerns, patients report minimal difficulties with the
follow-up process and a desire to continue their follow-up with
oncologists (See Fig. 1).
Discussion
This is, to our knowledge, the first qualitative study investigating
patient and clinician experiences with surveillance after resection
of pancreatic and peri-ampullary cancer. These malignancies are
unique in their high propensity for recurrence, overall poor sur-
vival and non-curative treatment when recurrence develops. The
recommended follow-up regimen for these patients remains one
of the most intense of all malignancies. In spite of the demands of
surveillance, the patients in our study noted few difficulties with
the follow-up process. Patients express an intense desire for
reassurance and derive this from their follow-up, despite addi-
tional anxiety related to the investigations. This is consistent with
the literature from other cancer sites.29–35 The clinicians inter-
viewed in our study recognized this need for reassurance in their
patients and provide intensive follow-up in response; however,
they do acknowledge the limited evidence to support the benefits
of surveillance in this patient population and the potential harms
of surveillance. The clinicians also suggest follow-up has
secondary benefits including maintaining the doctor–patient
relationship.
Patients and clinicians in our study exhibited a major discon-
nect in their respective understanding of the risk of recurrence
and prognosis after resection for pancreatic cancer. Both groups
recognized that discussions surrounding risk of recurrence had
occurred; however, patients, especially those with poor prognostic
factors, had unrealistic expectations of the benefits of treatment.
Figure 1 Overarching theory for patient and clinician views of
follow-up after pancreatic cancer surgery
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For example, one patient with recurrent disease expected to live
another ten years and another patient with a positive margin and
nodal involvement expected chemotherapy and radiation to ‘look
after that’ and be ‘healthy for another thirty years’. Our study was
unable to determine if there exists a difference in expectations
based on different stages of disease; however, it did appear that
patients with a poorer prognosis, including recurrent disease, had
a worse understanding of their prognosis. While surprising, this is
in keeping with other studies that have shown poor patient under-
standing of cancer prognosis.36–39 Other studies have revealed that
patients note improved satisfaction and less depression or anxiety
when their desire for prognostic information is met and when
their interactions with clinicians are perceived as open and
honest.36,38,40 Notably, no studies suggest patient outcomes are
worse after being informed of a poor prognosis.36,38,40 The clini-
cians in our study either felt patients implicitly knew the aggres-
sive biology of pancreatic cancer or had discussed prognosis but
avoided focusing on the recurrence rate. Studies have noted that
physicians struggle with individualizing the information for each
patient and ensuring patients understand their prognosis while
still providing hope.36,41
Our study is limited in that it was confined to one cancer centre;
it is possible that patients at other cancer centres understand their
prognosis better and have more realistic expectations. However,
our centre includes four hepatopancreaticobiliary surgeons, five
gastrointestinal medical oncologists and four gastrointestinal
radiation oncologists, all of whom treat patients with pancreatic
cancer. Thus, patients were treated by a heterogeneous group of
experienced clinicians who reported remarkably similar mis-
understandings and unrealistic expectations. It is possible that
patients on clinical trials may have a different understanding. The
results of this study are likely transferable to other centres with
similar patient populations; however, studies from other centres,
especially those with patients of different cultural and socioeco-
nomic backgrounds as well as those on clinical trials, would be
valuable.
A second limitation was the difficulty in recruiting patients
with recurrent disease due to physical discomfort, functional
decline and missed clinic appointments. Thus, the majority of our
findings were identified by patients undergoing active surveillance
yet without evidence of recurrence. It is possible that perspectives
on follow-up would change after recurrence, although we did not
observe a difference in the limited number of patients who we
interviewed with recurrence.
Interviews were not designed to identify barriers to effective
patient–clinician communication or reasons for unrealistic expec-
tations. It is possible that clinicians included in this study avoided
discussing prognosis with the patients or presented unclear infor-
mation, although the heterogeneity and experience of the clini-
cians included makes this unlikely. Clinician hopefulness or a
desire to provide reassurance may have affected the patients’
understanding of their prognosis. It is also possible that patients
seek reassurance so strongly that they consciously or subcon-
sciously perceived the information presented differently. However,
as this study did not directly observe the patient–clinician inter-
actions, it is not possible to determine the cause for this discon-
nect. It is known that patients receive an overwhelming burden of
information during the early phases of their cancer journey and
do not retain all of it.42–44 Further research is needed to identify
patient information needs and optimal techniques of presenting
information, such as repetitive education methods, particularly
surrounding prognosis. Studies should also explore barriers and
facilitators to effective patient–clinician communication at this
vulnerable time in a patient’s cancer journey.
Patients desire active surveillance after resection of pancreatic
cancer and clinicians generally support intense follow-up.
However, patients and clinicians express discordant goals moti-
vating the follow-up process. Patients seek follow-up to obtain
reassurance that the cancer has not returned, whereas clinicians
provide surveillance to maintain the doctor–patient relationship
as well as facilitate further treatments, palliative care and end-of-
life planning. There exists a conflict between the patient’s desire
for reassurance and clinicians knowledge of prognosis. In many
cases, patients exhibit unrealistic expectations of risk of recur-
rence and treatment benefits. Efforts to improve patient–
physician communication at this particularly vulnerable point in
the cancer journey would be valuable. Future studies should iden-
tify what information patients wish to know and how they wish to
receive this information, which we are currently investigating, as
well as clarify whether the addition of imaging to the follow-up
regimen, as is currently recommended, is beneficial.
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